Kyverna therapeutics provides business update and reports first quarter 2024 financial results

Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurology treated 30 patients cumulatively as of may 14, 2024, including eight patients with myasthenia gravis, seven patients with lupus nephritis, and four patients with multiple sclerosis strong balance sheet, bolstered by recent public offering emeryville, calif. , may 14, 2024 /prnewswire/ -- kyverna therapeutics, inc. (nasdaq: kytx), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today reported its business highlights and financial results for the first quarter ended march 31, 2024.
KYTX Ratings Summary
KYTX Quant Ranking